U.S. markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.84+0.46 (+2.99%)
At close: 4:00PM EDT

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
http://www.celldex.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees127

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony S. MarucciFounder, Pres, CEO & Director919.74kN/A1962
Dr. Tibor KelerFounder, Chief Scientific Officer & Exec. VP582.21kN/A1959
Mr. Sam MartinSr. VP, CFO, Sec. & Treasurer485.33kN/A1971
Ms. Elizabeth CrowleyChief Product Devel. Officer & Sr. VP457.96kN/A1972
Dr. Margo Heath-Chiozzi M.D.Sr. VP of Regulatory Affairs490.52kN/A1957
Ms. Sarah CavanaughSr. VP of Corp. Affairs & Admin.N/AN/A1975
Dr. Ronald A. PepinChief Bus. Officer & Sr. VPN/AN/A1956
Dr. Richard M. Wright Ph.D.Chief Commercial Officer & Sr. VPN/AN/A1964
Dr. Diane C. YoungSr. VP & Chief Medical OfficerN/AN/A1957
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Corporate Governance

Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of October 31, 2019 is 4. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.